Stephanie Brown, the SVP of rare diseases at Ipsen Biopharmaceuticals, explains how the company has continued its commitment to rare disease organizations — including those dedicated to acromegaly and fibrodysplasia ossificans progressiva (FOP) — during the Covid pandemic.
“Although our work with patient-advocacy organizations has been a bit different this year due to the pandemic, we were able to pivot quickly and find new ways to engage with them and provide critical health information and resources for the patients that we serve,” Brown said.
Ipsen develops and markets medications used in oncology, neuroscience and rare diseases, as well as consumer healthcare products.
In September, the company shared data from its growing Rare Diseases Therapeutic Area portfolio at the American Society for Bone and Mineral Research (ASBMR) annual meeting. This included the oral presentation of Ipsen’s MOVE trial, the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva (FOP). The data, presented by Robert Pignolo, MD, of the Mayo Clinic, describes the trial outcomes of the oral investigational therapy palovarotene in reducing new heterotopic ossification (HO) volume in 107 pediatric and adult patients with FOP. The MOVE efficacy results were compared with data from untreated patients from Ipsen’s Natural History Study (NHS).
Learn more about FOP and other rare bone diseases.